Well, yeah, that's sort of the nature of stats. Increased volume = increased potential data output.
Also, the statement here is a little off:
5% of the batches appear to have produced 90% of the adverse reactions
This is true, but look closer at the data. Those 5% of batches also have about 90% of the doses administered. Look down the list, and the vast majority of batches only have a handful of doses that are being tracked. So, it's very reasonable to expect those top 5% to have most of the adverse events
Well, yeah, that's sort of the nature of stats. Increased volume = increased potential data output.
Also, the statement here is a little off:
This is true, but look closer at the data. Those 5% of batches also have about 90% of the doses administered. Look down the list, and the vast majority of batches only have a handful of doses that are being tracked. So, it's very reasonable to expect those top 5% to have most of the adverse events
Check the numbers for Moderna, J&J / Janssen. Might be different ratios.
They tell a similar story, actually. Aside from one Moderna batch that had a big 15% ratio deaths/non, at 29 for 196.
That's an extreme outlier though. Most hover around 2%